Ebola disease is a severe and often life-threatening illness that requires urgent medical attention and specialized care. While this infection carries serious risks, modern medicine offers both supportive treatments and newly approved therapies that can significantly improve survival rates when administered early.

How Medical Teams Fight a Deadly Infection

Ebola disease emerges as one of the most challenging viral infections to manage, with outcomes heavily dependent on how quickly treatment begins and what medical resources are available. The main goal when treating this infection is to keep patients alive long enough for their own immune systems to fight off the virus, while simultaneously managing the severe symptoms that can rapidly develop. Treatment strategies differ based on which strain of the virus is involved, how far the disease has progressed, and what medical facilities are accessible to the patient.

The approach to managing Ebola has evolved considerably since the virus was first discovered in 1976 near the Ebola River in what is now the Democratic Republic of the Congo. Early outbreaks saw mortality rates climb as high as 90 percent, largely because medical teams had little understanding of how to support patients through the acute phase of illness. Today, with improved supportive care techniques and the recent approval of specific antiviral treatments for certain Ebola strains, death rates have decreased substantially in well-equipped medical facilities.^[1][2]

Medical authorities including the World Health Organization and the United States Centers for Disease Control have established clinical guidelines that help healthcare providers recognize Ebola quickly and initiate appropriate care. These guidelines emphasize that treatment must begin as soon as possible after symptoms appear, since the window of opportunity for intervention narrows rapidly as the disease progresses. Healthcare teams must also balance aggressive treatment with strict infection control measures to protect medical staff and prevent the virus from spreading within healthcare facilities.^[13]

The treatment landscape varies dramatically depending on the specific virus involved. Currently, approved vaccines and treatments exist only for Ebola virus disease (caused by the Zaire strain), while other forms such as Sudan virus disease and Bundibugyo virus disease still rely primarily on supportive care, though candidate products are under development.^[2][10]

Standard Treatment Approaches

The foundation of Ebola treatment rests on intensive supportive care, which means providing medical interventions that help the body cope with the damage caused by the virus while the immune system works to clear the infection. This supportive approach has proven crucial to survival, as patients with access to comprehensive supportive care show significantly better outcomes than those without it. The core principle is straightforward: keep vital organs functioning, maintain fluid balance, and manage symptoms aggressively until the patient’s immune system can gain the upper hand.^[2][10]

One of the most critical components of supportive care is rehydration therapy. Ebola causes severe fluid loss through multiple routes—patients often experience profuse vomiting, intense diarrhea, and sometimes bleeding. This fluid loss can quickly lead to dehydration, a condition where the body lacks sufficient water and electrolytes to function properly. Dehydration causes blood pressure to drop, organs to fail, and can ultimately result in shock, where the body’s tissues don’t receive enough blood flow to survive. Medical teams combat this by administering large volumes of intravenous fluids, carefully formulated to replace not just water but also essential salts and minerals that regulate heart rhythm, muscle function, and other vital processes.^[2][4]

Replacing blood components becomes necessary when patients develop bleeding complications. The virus can trigger a dangerous condition called disseminated intravascular coagulation, where the blood’s clotting system goes haywire—small clots form throughout the bloodstream while simultaneously the blood loses its ability to clot where needed. To address this, doctors may administer coagulation factors (proteins that help blood clot) and sometimes heparin (a medication that prevents abnormal clot formation). These interventions require careful monitoring because getting the balance wrong can worsen either bleeding or clotting problems.^[4][12]

Symptom management extends beyond fluids and blood products. Patients receive medications to control fever, which can climb dangerously high during Ebola infection. Pain relief is essential, as patients commonly experience severe headaches, muscle aches, and abdominal pain. Anti-nausea medications help reduce vomiting, which not only improves patient comfort but also helps prevent further fluid loss. Nutritional support becomes important during the recovery phase, as many patients lose their appetite entirely and require careful nutritional planning to regain strength.^[3][8]

The duration of supportive care varies considerably depending on disease severity. Patients who survive typically need intensive medical support for one to two weeks before their condition stabilizes. However, recovery doesn’t end when the acute symptoms resolve. Survivors may continue to experience complications for months after leaving the hospital, including persistent fatigue, joint pain, vision problems, and neurological symptoms. This extended recovery period requires ongoing medical monitoring and supportive interventions.^[14]

Treatment with standard approaches also includes careful monitoring for secondary infections. Patients with Ebola often develop bacterial infections on top of their viral illness, particularly if they have spent extended periods in intensive care. These secondary infections require antibiotic treatment and add complexity to patient management. Similarly, in regions where Ebola occurs, patients may have other endemic diseases like malaria that need simultaneous treatment.^[13]

Treatment in Clinical Trials

The devastating West African Ebola outbreak from 2014 to 2016, which resulted in more than 28,000 cases and over 11,000 deaths, catalyzed an unprecedented research effort to develop specific treatments for Ebola virus disease. This work culminated in significant breakthroughs, particularly for infections caused by the Zaire ebolavirus strain, which is responsible for most large outbreaks and has historically shown the highest mortality rates.^[3][11]

The most significant advancement came in October 2020 when the United States Food and Drug Administration approved atoltivimab/maftivimab/odesivimab (marketed as Inmazeb), making it the first approved treatment specifically for Zaire ebolavirus infection. This therapy represents a class of drugs called monoclonal antibodies, which are laboratory-made proteins designed to mimic the immune system’s ability to fight off harmful viruses. The treatment consists of a cocktail of three different monoclonal antibodies that work together to neutralize the Zaire ebolavirus.^[11][12]

The way Inmazeb works is quite specific: each of the three antibodies recognizes and binds to a particular part of the virus’s surface glycoprotein, which is the protein the virus uses to attach to and enter human cells. By binding to these sites, the antibodies essentially block the virus from infecting new cells. Additionally, when antibodies coat the virus, they mark it for destruction by other parts of the immune system, helping the body clear the infection more rapidly. This multi-pronged approach explains why a combination of three antibodies works better than a single antibody—it attacks the virus at multiple points simultaneously, making it much harder for the virus to escape through mutation.^[11]

The approval of Inmazeb was based on evidence from a randomized controlled clinical trial conducted in the Democratic Republic of the Congo during an active outbreak. This Phase III trial, which compares new treatments directly against standard care or other treatments in large groups of patients, demonstrated that the antibody cocktail significantly reduced mortality compared to supportive care alone. The treatment is indicated for both adults and children, including newborn babies born to mothers who tested positive for Zaire ebolavirus infection.^[11][12]

Shortly after Inmazeb’s approval, another monoclonal antibody treatment called Ebanga (ansuvimab) also received FDA approval for treating Zaire ebolavirus infection. Unlike Inmazeb’s three-antibody approach, Ebanga uses a single monoclonal antibody. Clinical trial data showed it too could improve survival rates when administered to patients with confirmed Zaire ebolavirus infection. Both treatments must be given intravenously, meaning they are delivered directly into the bloodstream through a vein, and they work best when started as early as possible after symptoms begin.^[11][7]

Research efforts have also explored other types of antiviral drugs. One promising approach involves nucleoside analogue inhibitors, which are compounds that interfere with viral replication by targeting enzymes the virus needs to copy itself. Specifically, scientists have studied drugs that inhibit an enzyme called S-adenosylhomocysteine hydrolase. In laboratory studies using mice infected with mouse-adapted Ebola virus, these drugs showed the ability to block virus replication. The mechanism works indirectly—by inhibiting this enzyme, the drugs prevent certain chemical reactions that the virus needs to complete its life cycle. Animal studies demonstrated dose-dependent responses, meaning higher doses produced stronger antiviral effects. However, these drugs are still in earlier phases of development and have not yet been approved for human use.^[12]

A critical gap remains in treatment options for other Ebola species. While Sudan virus disease and Bundibugyo virus disease can cause outbreaks with mortality rates ranging from 25 to 90 percent, no approved treatments exist specifically for these viruses. The monoclonal antibodies developed for Zaire ebolavirus don’t work against other Ebola species because the viral proteins differ enough that the antibodies can’t recognize and bind to them. This became evident during the 2022 Sudan ebolavirus outbreak in Uganda, where healthcare providers could only offer supportive care since no Sudan virus-specific treatments were available.^[2][11]

Researchers are actively working to fill this gap through ongoing clinical trials. Several candidate treatments for Sudan virus disease are in various stages of development. These include new monoclonal antibody combinations designed specifically to target Sudan virus proteins, as well as broad-spectrum antiviral compounds that might work against multiple Ebola species. Such trials typically begin with Phase I studies, which test safety in small numbers of healthy volunteers, before progressing to Phase II studies that evaluate whether the treatment produces the desired effect in patients with the disease.^[2][11]

Prevention through vaccination has also seen major progress. A vaccine called rVSV-ZEBOV (marketed as Ervebo or V920) received FDA approval in 2019 for preventing Ebola virus disease caused by Zaire ebolavirus. This vaccine uses a novel platform: it’s built on a weakened form of vesicular stomatitis virus (a virus that normally infects livestock) that has been genetically engineered to carry a gene for the Ebola virus glycoprotein. When injected, the vaccine triggers the immune system to produce antibodies against the Ebola protein without causing disease.^[9][12]

The Ervebo vaccine proved remarkably effective during real-world deployment. During the 2014-2016 West African outbreak, researchers conducted a groundbreaking study called the ring vaccination trial in Guinea. This innovative approach involved vaccinating people who had been in contact with confirmed Ebola cases (the “ring” around the patient) rather than vaccinating entire populations. Results were striking: among people who received the vaccine, no Ebola cases occurred 10 days or more after vaccination, while 23 cases developed in unvaccinated contacts. This translated to an efficacy rate of approximately 97.5 percent. The vaccine was also deployed during the 2018-2020 outbreak in the Democratic Republic of the Congo, where it protected approximately 90,000 individuals.^[12]

Clinical trials for Ebola treatments and vaccines are conducted in multiple locations, though outbreak settings in Africa have provided the most critical real-world testing environments. When outbreaks occur in countries like the Democratic Republic of the Congo, Uganda, or Guinea, international health organizations rapidly mobilize to offer experimental treatments under expanded access protocols or formal clinical trial structures. This approach serves dual purposes: it provides potentially life-saving treatments to outbreak victims while simultaneously generating data about treatment effectiveness and safety. Trials have also been conducted in the United States and Europe, particularly for vaccine studies involving healthy volunteers.^[11][12]

Patient eligibility for clinical trials typically depends on several factors. For treatment trials, participants usually must have laboratory-confirmed Ebola infection, be within a certain timeframe since symptom onset, and meet specific health criteria. For vaccine trials, eligibility varies by study phase—early phase studies enroll healthy volunteers, while later phase studies during outbreaks may focus on high-risk groups such as healthcare workers, contacts of confirmed cases, or people living in outbreak areas. Pregnant women and young children were historically excluded from many trials, but recent studies have begun including these vulnerable populations given that they are also at risk during outbreaks.^[11][13]

The preliminary results from various clinical trials have been encouraging but also highlight the complexity of treating Ebola. In treatment trials, monoclonal antibodies showed clear benefits in reducing mortality, particularly when given early in the course of illness. Safety profiles have generally been acceptable, with most patients tolerating the treatments well. However, no treatment has proven 100 percent effective—some patients still die despite receiving cutting-edge therapies, especially if treatment begins late or if patients have very high viral loads when treatment starts. This underscores the critical importance of early detection and prompt treatment initiation.^[11]

Most common treatment methods

• Supportive care and fluid management
  • Intensive intravenous rehydration to replace fluids lost through vomiting, diarrhea, and bleeding
  • Electrolyte replacement to maintain proper body chemistry
  • Replacement of blood components and coagulation factors when bleeding complications occur
  • Use of heparin to manage disseminated intravascular coagulation
  • Monitoring and support of vital organ function including kidneys, liver, and heart
• Symptom management medications
  • Fever-reducing medications to control high body temperatures
  • Pain relief drugs for severe headaches, muscle pain, and abdominal discomfort
  • Anti-nausea medications to reduce vomiting
  • Nutritional support during acute illness and recovery phases
  • Antibiotics to treat secondary bacterial infections
• Monoclonal antibody therapy
  • Atoltivimab/maftivimab/odesivimab (Inmazeb) – three-antibody cocktail approved for Zaire ebolavirus infection
  • Ansuvimab (Ebanga) – single monoclonal antibody approved for Zaire ebolavirus infection
  • Both work by binding to viral surface proteins to prevent infection of new cells
  • Most effective when administered early after symptom onset
  • Given intravenously in hospital settings
• Vaccination
  • rVSV-ZEBOV (Ervebo) vaccine approved for preventing Zaire ebolavirus infection
  • Uses genetically engineered vesicular stomatitis virus carrying Ebola virus glycoprotein gene
  • Demonstrated 97.5 percent efficacy in ring vaccination trials
  • Used for high-risk populations including healthcare workers and contacts of confirmed cases
  • Single-dose administration provides protection
• Experimental antiviral approaches
  • Nucleoside analogue inhibitors targeting S-adenosylhomocysteine hydrolase enzyme
  • Broad-spectrum antivirals in development for multiple Ebola species
  • Candidate monoclonal antibodies for Sudan virus disease in clinical trials
  • Most remain in early-phase research and not yet approved for routine use